Trends in Innovation and the Business of Drug Discovery
2.9 CONCLUDING REMARKS
2.8.6 Building the Pharmaceutical Ecosystem
Effective integration of all aspects of the pharmaceutical ecosystem will lead to high performance standards. For example, a cross-functional team of professionals concerned with drug discovery could work out a proof of concept in the clinical phase to design a compound capable of filling the gaps in regards to patient, regulator, and payer needs. This will enhance pro- ductivity and lower total healthcare costs and technological “spillovers” that will benefit the general society.
Trends in Innovation and the Business of Drug Discovery 53
[9] Friedrman J, Gerlowski DA, Silberman J. What attracts foreign multinational corporations? Evidence from branch plant location in the United States. J Reg Sci 2006;32(4):403–18.
[10] Buente M, Danner S, Weissbäcker S, Rammé C. Pharma Emerging Markets 2.0: How Emerging Markets Are Driving the Transformation of the Pharmaceutical Industry.
New York, NY: Booz & Company; 2013.
[11] Innovation.org, Great moments in innovation [Internet]; 2014. Available from: http://
www.innovation.org/index.cfm/nonav/Great_Moments_in_Innovation [accessed No- vember, 2014].
[12] National Institute of Allergy and Infectious Disease. Tuberculosis (TB), age of optimism [Internet]; 2014. Available from: http://www3.niaid.nih.gov/topics/tuberculosis/
Research/researchFeatures/history/historical_optimism.htm [accessed 01.11.2014].
[13] Innovation.org, Great moments in innovation [Internet]; 2014. Available from: http://www.
innovation.org/index.cfm/nonav/Great_Moments_in_Innovation [accessed 01.11.2014].
[14] NIH, National Institute of Allergy and Infectious Disease, Tuberculosis (TB), age of optimism [Internet]; 2014. Available from: http://www3.niaid.nih.gov/topics/tuberculosis/
Research/researchFeatures/history/historical_optimism.htm [accessed 03.11.2014].
[15] Kaplan W, Laing R. Priority medicines for Europe and the World. World Health Organization Department of Essential Drugs and Medicines Policy; 2004. Available from: http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf
[16] Bradley S, Weber J. The pharmaceutical industry: challenges of the new century.
Harvard Business School; 2003. Available from: http://www.ramos.utfsm.cl/doc/169/
sc/Casopharmaceuticalindustry.pdf
[17] Hewitt J, Campbell DJ, Cacciotti J. Beyond the shadow of a drought. Life and Health Sciences; 2011. Available from: http://www.oliverwyman.com/content/dam/
oliver-wyman/global/en/files/archive/2011/OW_EN_HLS_PUBL_2011_Beyond_
the_Shadow_of_a_Drought(3).pdf
[18] Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191–200. (“Why drug development is failing – and how to fix it” published later in 2012).
[19] Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959–68.
[20] Ahmed R. The patent cliff: implications for the pharmaceutical [Internet]; 2014.
Available from: http://triplehelixblog.com/2014/07/the-patent-cliff-implications-for- the-pharmaceutical-industry/#sthash.ILnShoIC.ReC80vJx.dpuf [accessed 03.11.2014].
[21] Top 10 best-selling drugs of the 21st century [Internet]; 2014. Available from: http://
www.genengnews.com/insight-and-intelligenceand153/top-10-best-selling-drugs-of- the-21st-century/77899716/ [accessed 04.11.2014].
[22] This patent cliff 2014 chart shows how much revenue big pharma will lose [Internet];
2014. Available from: http://triplehelixblog.com/2014/07/the-patent-cliff-implications- for-the-pharmaceutical-industry/#sthash.ILnShoIC.dpuf [accessed 03.11.2014].
[23] Tse MT, Kirkpatrick P. 2012 in reflection. Nat Rev Drug Discov 2013;12:8–10.
[24] Gupta RR, Gifford EM, Liston T, Waller CL, Hohman M, Bunin BA, Ekins S. Using open source computational tools for predicting human metabolic stability and additional ADME/TOX properties. Drug Metab Dispos 2013;38(11):2083–90.
[25] Hohman M, Gregory K, Chibale K, Smith PJ, Ekins S, Bunin B, Hohman. Novel web- based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today 2009;14:261–70.
[26] PhRMA members leading the way in search for new medicines and cures [Internet];
2014. Available from: http://www.phrma.org/about#sthash.B8mtKP0E.cpiALkJl.dpuf [accessed 06.11.2014].
[27] Treatment advances transform HIV/AIDS [Internet]; 2014. Available from: http://
innovation.org/timelines/treatment-advances-transform-hiv/aids [accessed 05.11.2014].
[28] Innovative treatments for rheumatoid arthritis improve the lives of patients [Internet]; 2014.
Available from: http://innovation.org/gallery/innovative-treatments-for-rheumatoid- arthritis-improve-the-lives-of-patient [accessed 04.11.2014].
[29] Chronic leukemias: survival rates [Internet]; 2014. Available from: http://www.un.org/
millenniumgoals/reports.shtl. http://innovation.org/chronic-leukemias-survival-rates- rise [accessed 07.11.2014].
[30] The Millennium Development Goals Report 2014 [Internet]; 2014. Available from:
http://www.un.org/millenniumgoals/reports.shtl [accessed 07.11.2014].
[31] Challenge and opportunity on the critical path to new medical products. Innovation Stagnation. U.S. Department of Health and Human Services. Food and Drug Administration; 2004. Available from: http://spores.nci.nih.gov/applicants/guidelines/
guidelines_full.html#1b
[32] Eggermont A, Newell H. Translational research in clinical trials: the only way forward.
Eur J Cancer 2001;37.
[33] Rowett L. U.K. initiative to boost translational research. J Natl Cancer Instit 2002;94(10).
[34] Kaitin KI. Deconstructing the drug development process: the new face of innovation.
Clin Pharmacol Therapeut 2010;87(3):356–61.
[35] Del Lino J. Discussion point: should governments buy drug patents? Eur J Health Econ 2007;8:173–7.
[36] Grunberg E, Schnitzer RJ. Studies on the activity of hydrazine derivatives of isonicotinic acid in the experimental tuberculosis of mice. Q Bull Sea View Hosp 1952;13:3–11.
[37] Pletscher A. The discovery of antidepressants: a winding path. Experientia 1991;47:4–8.
[38] Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3:451–6.
[39] Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem?
JAMA 1999;281(18):1728–34.
[40] Cockburn I. The changing structure of the pharmaceutical industry. Health Affairs 2004;23(1):10–22.
[41] Drews J. Drug discovery: a historical perspective. Science 2000;287(5460):1960.
[42] Kaitin KI, Eve SR. Explaining the drug drought. PharmExec.com 2010 [Internet];
2014. Available from: http://www.pharmexec.com/pharmexec/Explaining-the-Drug- Drought/ArticleStandard/Article/detail/687358 [accessed 05.11.2014].
[43] Horrobin DF. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2003;2(2):151–4.
[44] Hammer O. Lessons learned from Sanofi-Aventis’s Phase III failure. Seeking-Alpha [Internet]; 2014. Available from: http://seekingalpha.com/article/250527-lessons- learned-from-sanofiaventis-s-phase-iii-failure [accessed 09.11.2014].
[45] Top 10 clinical trial failures of 2012 [Internet]; 2014. Available from: http://www.
genengnews.com/insight-and-intelligenceand153/top-10-clinical-trial-failures- of-2012/77899765/ [accessed 09.11.2014].
[46] Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203–14.
[47] Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079–81.
[48] Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.
[49] Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens.
Infect Control Hosp Epidemiol 2010;31(Suppl. 1):S7–S10.
[50] Gilbert DN, Guidos RJ, Boucher HW, Talbot GH, Spellberg B, Edwards JE Jr, Scheld WM, Bradley JS, Bartlett JG. The 10 × ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Infectious Diseases Society of America.
Clin Infect Dis 2010;50:1081–3.
Trends in Innovation and the Business of Drug Discovery 55
[51] Tallman G, Brock J. Pipeline or pipe dream: new antibiotics for multidrug-resistant gram-negative bacilli. Infectious Disease News; 2013. Available from: http://www.
healio.com/infectious-disease/emerging-diseases/news/print/infectious-disease- news/%7B2d636304-7271-44d3-98a7-fd061a787883%7D/pipeline-or-pipe-dream- new-antibiotics-for-multidrug-resistant-gram-negative-bacilli
[52] Leisinger KM. Meeting the global health challenge: the role of the pharmaceutical industry. Making It Magazine; 2012. Available from: http://www.makingitmagazine.
net/?p=6046
[53] Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203–14.
[54] McBride R. 7 Major pharmas unite with academics in €196M discovery effort [Internet];
2013. Available from: http://muse.jhu.edu/journals/ens/summary/v007/7.3rooij.html [accessed 10.11.2014].
[55] Burrill GS. Biotech2013 - Life Sciences – Capturing Value. Beijing, China: Burrill &
co; 2013.
[56] Rooij AV. Shaping the industrial century: the remarkable story of the evolution of the modern chemical and pharmaceutical industries. Enterprise Soc 2006;7(3):624–6.
[57] Sanofi reinforces its presence in Morocco [Internet]. Press Release; 2013. Avaliable from: http://www.bloomberg.com/article/2013-04-17/a0xAyJyVL7J4.html [accessed 11.11.2014].
[58] Chesbrough H, Rosenbloom RS. The role of the business model in capturing value from innovation: evidence from Xerox Corporation’s technology spin-off companies.
Ind Corp Change 2002;11:529–55.
[59] Finn BM, Sutherland CF. The pharmaceutical industry: where it is, how it got here, where it needs to go, how to get there. Int J Med Market 2004;4(4):361–9.
[60] Carroll J. UPDATED: GlaxoSmithKline bags genetic vaccine developer Okairos for $325 million [Internet]. 2013. FierceBiotech. Available from: http://www.
fiercebiotech.com/story/glaxosmithkline-bags-genetic-vaccine-developer-okairos- 325-million/2013-05-29 [accessed 12.11.2014].
[61] FDA OKs bioMérieux diagnostic for GSK’s cancer drugs [Internet]; 2013. FierceMedical Devices. Available from: http://www.fiercemedicaldevices.com/story/fda-oks-biom- rieux-diagnostic-gsks-cancer-drugs/2013-05-29 [accessed 12.11.2014].
Social Aspects of Drug Discovery, Development and Commercialization Copyright © 2016 Elsevier Inc.
http://dx.doi.org/10.1016/B978-0-12-802220-7.00003-X All rights reserved. 57